Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).

Bortezomib for maintenance, consolidation ups survival in multiple myeloma

26 Apr 2020

Bortezomib-based consolidation and maintenance therapies for multiple myeloma improve survival but come with safety concerns, reports a recent meta-analysis.

Accessing the databases of Embase, Web of Science and PubMed, researchers retrieved ten randomized controlled trials (n=3,147), in which bortezomib-containing regimens were compared to other treatments or to observation. Outcomes included progression-free (PFS) and overall (OS) survival, as well as the occurrence of adverse events.

Bortezomib-based maintenance therapies showed significant efficacy in boosting PFS (hazard ratio [HR], 0.72, 95 percent confidence interval [CI], 0.55–0.95; p=0.02) and OS (HR, 0.71, 95 percent CI, 0.58–0.87; p=0.001). Excluding transplant-ineligible patients attenuated the effect on PFS, but only slightly (HR, 0.94, 95 percent CI, 0.699–1.001; p=0.052). The benefit on OS remained significant (HR, 0.72, 95 percent CI, 0.54–0.96; p=0.025).

In comparison, bortezomib-based consolidation therapies improved only PFS (HR, 0.77, 95 percent CI, 0.68–0.88; p<0.001) but not OS (HR, 0.98, 95 percent CI, 0.78–1.24; p=0.87). Excluding one study did not change this.

In terms of safety, researchers also found that bortezomib-containing consolidation and maintenance therapies came with a higher risk of grade 3 neurologic symptoms that was of borderline significance (risk ratio [RR], 1.59, 95 percent CI, 0.94–2.69; p=0.08).

There were also nonsignificant increases in the likelihood of developing gastrointestinal symptoms (RR, 1.66, 95 percent CI, 0.71–3.88; p=0.24) and fatigue (RR, 2.10, 95 percent CI, 0.83–5.30; p=0.12).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).